View in EDS HTML Full Text PDF Full Text

Real-world use of Safinamide in motor fluctuating Parkinson's disease patients in Italy.

Saved in:
Bibliographic Details
Title: Real-world use of Safinamide in motor fluctuating Parkinson's disease patients in Italy.
Authors: Bovenzi, Roberta (AUTHOR), Liguori, Claudio (AUTHOR), Canesi, Margherita (AUTHOR), D'Amelio, Marco (AUTHOR), De Pandis, Maria Francesca (AUTHOR), Marini, Carmine (AUTHOR), Monge, Alessandra (AUTHOR), Padovani, Alessandro (AUTHOR), Tessitore, Alessandro (AUTHOR), Stefani, Alessandro (AUTHOR), Zappia, Mario (AUTHOR), for the SYNAPSES Study Investigators Italian Group (AUTHOR), Abbruzzese, G. (AUTHOR), Aguggia, M. (AUTHOR), Avarello, T. (AUTHOR), Barone, P. (AUTHOR), Bentivoglio, A. R. (AUTHOR), Bosco, D. (AUTHOR), Calabresi, P. (AUTHOR), Callegarini, C. (AUTHOR)
Source: Neurological Sciences. Feb2024, Vol. 45 Issue 2, p573-583. 11p.
Subjects: Parkinson's disease, People with mental illness, Movement disorders
Geographic Terms: Italy
Abstract: Introduction: Safinamide is a recent antiparkinsonian drug that modulates both dopaminergic and glutamatergic systems with positive effects on motor and nonmotor symptoms of Parkinson's disease (PD). Here, we aimed to describe the efficacy and safety of safinamide in the Italian PD patients in real-life conditions. Methods: We performed a sub-analysis of the Italian cohort of the SYNAPSES study, a multi-country, multi-center, retrospective-prospective cohort observational study, designed to investigate the use of safinamide in routine clinical practice. Patients received for the first time a treatment with safinamide and were followed up for 12 months. The analysis was conducted on the overall population and in subgroups of interest: i) patients > 75 years, ii) patients with relevant comorbidities and iii) patients affected by psychiatric symptoms. Results: Italy enrolled 616/1610 patients in 52 centers, accounting for 38% of the entire SYNAPSES cohort. Of the patients enrolled, 86.0% were evaluable at 12 months, with 23.3% being > 75 years, 42.4% with psychiatric conditions and 67.7% with relevant comorbidities. Safinamide was effective on motor symptoms and fluctuations as measured through the Unified PD rating scale III and IV scores, and on the total score, without safety issues in none of the subgroups considered. Conclusion: The SYNAPSES data related to Italian patients confirms the good safety profile of safinamide even in special groups of patients. Motor fluctuations and motor impairment improved at the follow-up suggesting the significant role of safinamide in managing motor symptoms in PD patients. [ABSTRACT FROM AUTHOR]
Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 174819407
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Real-world use of Safinamide in motor fluctuating Parkinson's disease patients in Italy.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Bovenzi%2C+Roberta%22">Bovenzi, Roberta</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Liguori%2C+Claudio%22">Liguori, Claudio</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Canesi%2C+Margherita%22">Canesi, Margherita</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22D'Amelio%2C+Marco%22">D'Amelio, Marco</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22De+Pandis%2C+Maria+Francesca%22">De Pandis, Maria Francesca</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Marini%2C+Carmine%22">Marini, Carmine</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Monge%2C+Alessandra%22">Monge, Alessandra</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Padovani%2C+Alessandro%22">Padovani, Alessandro</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tessitore%2C+Alessandro%22">Tessitore, Alessandro</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Stefani%2C+Alessandro%22">Stefani, Alessandro</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zappia%2C+Mario%22">Zappia, Mario</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22for+the+SYNAPSES+Study+Investigators+Italian+Group%22">for the SYNAPSES Study Investigators Italian Group</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Abbruzzese%2C+G%2E%22">Abbruzzese, G.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Aguggia%2C+M%2E%22">Aguggia, M.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Avarello%2C+T%2E%22">Avarello, T.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Barone%2C+P%2E%22">Barone, P.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bentivoglio%2C+A%2E+R%2E%22">Bentivoglio, A. R.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bosco%2C+D%2E%22">Bosco, D.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Calabresi%2C+P%2E%22">Calabresi, P.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Callegarini%2C+C%2E%22">Callegarini, C.</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Neurological+Sciences%22">Neurological Sciences</searchLink>. Feb2024, Vol. 45 Issue 2, p573-583. 11p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Parkinson's+disease%22">Parkinson's disease</searchLink><br /><searchLink fieldCode="DE" term="%22People+with+mental+illness%22">People with mental illness</searchLink><br /><searchLink fieldCode="DE" term="%22Movement+disorders%22">Movement disorders</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Italy%22">Italy</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Introduction: Safinamide is a recent antiparkinsonian drug that modulates both dopaminergic and glutamatergic systems with positive effects on motor and nonmotor symptoms of Parkinson's disease (PD). Here, we aimed to describe the efficacy and safety of safinamide in the Italian PD patients in real-life conditions. Methods: We performed a sub-analysis of the Italian cohort of the SYNAPSES study, a multi-country, multi-center, retrospective-prospective cohort observational study, designed to investigate the use of safinamide in routine clinical practice. Patients received for the first time a treatment with safinamide and were followed up for 12 months. The analysis was conducted on the overall population and in subgroups of interest: i) patients > 75 years, ii) patients with relevant comorbidities and iii) patients affected by psychiatric symptoms. Results: Italy enrolled 616/1610 patients in 52 centers, accounting for 38% of the entire SYNAPSES cohort. Of the patients enrolled, 86.0% were evaluable at 12 months, with 23.3% being > 75 years, 42.4% with psychiatric conditions and 67.7% with relevant comorbidities. Safinamide was effective on motor symptoms and fluctuations as measured through the Unified PD rating scale III and IV scores, and on the total score, without safety issues in none of the subgroups considered. Conclusion: The SYNAPSES data related to Italian patients confirms the good safety profile of safinamide even in special groups of patients. Motor fluctuations and motor impairment improved at the follow-up suggesting the significant role of safinamide in managing motor symptoms in PD patients. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=174819407
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10072-023-07001-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 573
    Subjects:
      – SubjectFull: Parkinson's disease
        Type: general
      – SubjectFull: People with mental illness
        Type: general
      – SubjectFull: Movement disorders
        Type: general
      – SubjectFull: Italy
        Type: general
    Titles:
      – TitleFull: Real-world use of Safinamide in motor fluctuating Parkinson's disease patients in Italy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Bovenzi, Roberta
      – PersonEntity:
          Name:
            NameFull: Liguori, Claudio
      – PersonEntity:
          Name:
            NameFull: Canesi, Margherita
      – PersonEntity:
          Name:
            NameFull: D'Amelio, Marco
      – PersonEntity:
          Name:
            NameFull: De Pandis, Maria Francesca
      – PersonEntity:
          Name:
            NameFull: Marini, Carmine
      – PersonEntity:
          Name:
            NameFull: Monge, Alessandra
      – PersonEntity:
          Name:
            NameFull: Padovani, Alessandro
      – PersonEntity:
          Name:
            NameFull: Tessitore, Alessandro
      – PersonEntity:
          Name:
            NameFull: Stefani, Alessandro
      – PersonEntity:
          Name:
            NameFull: Zappia, Mario
      – PersonEntity:
          Name:
            NameFull: for the SYNAPSES Study Investigators Italian Group
      – PersonEntity:
          Name:
            NameFull: Abbruzzese, G.
      – PersonEntity:
          Name:
            NameFull: Aguggia, M.
      – PersonEntity:
          Name:
            NameFull: Avarello, T.
      – PersonEntity:
          Name:
            NameFull: Barone, P.
      – PersonEntity:
          Name:
            NameFull: Bentivoglio, A. R.
      – PersonEntity:
          Name:
            NameFull: Bosco, D.
      – PersonEntity:
          Name:
            NameFull: Calabresi, P.
      – PersonEntity:
          Name:
            NameFull: Callegarini, C.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: Feb2024
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 15901874
          Numbering:
            – Type: volume
              Value: 45
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Neurological Sciences
              Type: main
ResultId 1